# Individual and structural benefits, challenges, and strategies for integrating medication assistance treatment and antiretroviral services for persons living with HIV who use drugs in Dar es Salaam, Tanzania

**Authors:** Dorothy Mushi, Peter Sakejo, Magreat Somba, David Huh, Deepa Rao, Sylvia Kaaya

PMC · DOI: 10.21203/rs.3.rs-8346864/v1 · Research Square · 2026-02-18

## TL;DR

This study explores the benefits and challenges of integrated HIV treatment for drug users in Tanzania and suggests strategies to improve care.

## Contribution

The study identifies structural and psychosocial barriers to HIV treatment for drug users and proposes targeted strategies to enhance service delivery.

## Key findings

- PUD-LWH reported improved mental and physical stability and family reintegration through IMAT services.
- Challenges include stigma, financial costs, and limited provider time.
- Proposed solutions include awareness campaigns, psychosocial support, and income-generation training.

## Abstract

People who use drugs (PWUDs) have an increased risk of acquiring and transmitting bloodborne diseases, including HIV, hepatitis B and C virus. To manage HIV among people who use drugs and live with HIV (PUD-LWH), health services provide integrated Medication-Assisted and Antiretroviral Treatment Services (IMAT services). Although the IMAT comprehensive care package includes biological, social, and psychological interventions, PUD-LWH’s retention in care is suboptimal. A formative needs assessment collected qualitative information to inform adaptation for PUD-LWH of an evidence-based peer-led group psychosocial intervention that showed good clinical and psychosocial outcomes in people living with HIV.

We conducted in-depth interviews with 22 PUD-LWH to understand users’ experiences with IMAT services. Healthcare providers (n=6) also participated. Thematic areas explored included perceptions of how the IMAT services process met users’ needs, experiences when attending IMAT services, including perceived benefits and challenges, and proposed strategies to overcome reported difficulties. Narrative data were analyzed using thematic analysis.

PUD-LWH perceived themselves as physically and mentally stable and acknowledged that IMAT had helped them re-integrate with families. Enacted stigma, out-of-pocket healthcare expenses, and limited time with healthcare providers due to an overburdened IMAT service were challenges to maintaining adherence to IMAT clinic visits and ART medication use. Participants proposed strategies to continue building awareness of IMAT services, reduce enacted stigma related to drug use, enhance client psychosocial care, facilitate the provision of skills for improving income generation for PUD-LWH, and increase the number of IMAT healthcare providers.

This formative study reveals individual, family, and community-level facilitators and barriers to accessing and using IMAT services and IMAT services-based structural challenges. IMAT services clients by suggesting strategies to overcome structural challenges.

## Linked entities

- **Diseases:** hepatitis B (MONDO:0005344)

## Full-text entities

- **Genes:** CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** MAT (MESH:C535434), heroin addiction (MESH:D006556), OUDs (MESH:D009293), bloodborne diseases (MESH:D004194), mental and physical disorders (MESH:D001523), drug addiction (MESH:D019966), hepatitis B and C virus (MESH:D006509), drug-related harm (MESH:D000081015), depressive symptom (MESH:D003866), hepatitis (MESH:D056486), HIV (MESH:D015658), overdosed (MESH:D062787), heroin withdrawal symptoms (MESH:D013375), bloodborne infections (MESH:D007239)
- **Chemicals:** MAT (MESH:C028526), opiates (MESH:D053610), alcohol (MESH:D000438), Heroin (MESH:D003932), ARV drugs (-), Methadone (MESH:D008691)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12935000/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12935000/full.md

---
Source: https://tomesphere.com/paper/PMC12935000